期刊文献+

甲硝唑结肠定位缓释片与普通片人体药代动力学对比研究 被引量:3

Pharmacokinetic comparison of metronidazole colon-targeted sustained-release tablets with conventional tablets in healthy volunteers
原文传递
导出
摘要 目的:采用RP-HPLC法测定人血浆中甲硝唑的浓度,对比研究甲硝唑结肠定位缓释片与普通片在健康人体内的药代动力学。方法:采用随机交叉自身对照试验设计,对12例健康受试者(男女各半)先后单次和多次口服受试制剂甲硝唑结肠定位缓释片与参比制剂甲硝唑普通片进行药代动力学对比研究。采用RP-HPLC法测定血药浓度、DAS 2.0药代动力学软件计算药代动力学参数、SPSS 17.0进行统计分析。结果:单次和多次口服甲硝唑结肠定位缓释片、甲硝唑普通片200 mg的血药浓度-时间曲线均符合二室开放模型。单次给药甲硝唑结肠定位缓释片与普通片的Tmax分别为(19.50±3.43)和(1.52±0.56)h,Cmax分别为(1.083±0.710)和(4.536±0.964)mg.L-1,AUC0~t分别为(22.69±15.96)和(62.90±14.51)mg.L-1.h,t1/2z分别为(10.60±1.62)和(9.83±2.02)h,CLz/F分别为(25.22±44.90)和(3.21±0.70)L.h-1,Vz/F分别为(378.59±661.63)和(44.18±7.90)L;多次给药甲硝唑结肠定位缓释片与普通片的Tmax分别为(11.25±4.58)和(1.05±0.57)h,Cmax分别为(3.84±1.32)和(7.96±1.33)mg.L-1,AUC0~t分别为(116.81±46.90)和(115.48±31.64)mg.L-1.h,AUCss分别为(39.88±14.33)和(60.07±12.03)mg.L-1.h,t1/2z分别为(10.65±1.64)和(10.13±2.27)h,CLz/F分别为(1.97±0.82)和(1.80±0.55)L.h-1,Vz/F分别为(29.49±11.04)和(24.94±4.45)L。结论:甲硝唑结肠定位缓释片与普通片比较,Tmax显著滞后,Cmax明显降低,表明其具有典型的缓释特征。 Objective: To determine metronidazole in human plasma by RP-HPLC method, and compare the pharmaeokineties of metronidazole colon-targeted sustained-release tablets with conventional tablets in Chinese healthy volunteers. Methods: Twelve healthy volunteers were enrolled to receive single dose and multiple-dose of metronidazole colon-targeted sustained-release tablets and conventional tablets according to a randomized cross-over design. Metronidazole concentration in plasma was determined by RP-HPLC method, and the pharmacokinetic pa- rameters were calculated by DAS 2.0 software. Statistical analysis was performed by SPSS 17.0 program. Results: The main pharmacokinetic parameters of metronidazole test and reference preparations after a single dose were as follows: Tmax (19. 50 ± 3. 43 ) h and (1.52 ±0.56) h, Cmax(1.083±0.710) mg·L-1 and (4.536 ±0.964) mg·L-1, AUC0-5(22.69 ±15.96) mg·L^-1·h and (62.90 ±14.51) mg·L-1·h, tl/2z (10.60 ±1.62) h and (9.83 ±2.02) h,CLz/F (25.22 ±44.90) L.h-1 and (3.21 ±0.70) L.h^-1, V/F (378.59 ±661.63) L and (44.18 ±7.90) L, respectively. The parameters after the multi-dose were : Tmax ( 11.25 ±4.58) h and ( 1.05± 0.57) h, C (3.84± 1.32) mg·L-1 and (7.96 ±1.33) mg·L-1, AUC0-t(116.81 ±46.90) mg·L-1·h and (115.48 +31.64) mg·L-1·h, AUC (39.88 ±14.33) mg.L^-1·h and (60.07 ±12.03) mg.L-1·h, t1/2z (10.65±1.64) h and (10.13 ±2.27) h, CLz/F (1.97±0.82) L·h-1 and (1.80±0.55) L·h-1, Vz/F (29.49 ±11.04) L and (24.94±4.45) L, re- spectively. Conclusion: Metronidazole colon-targeted sustained-release tablets have delayed T max and lower C in healthy Chinese volunteers, showing the typical sustained release characteristics.
出处 《中国新药杂志》 CAS CSCD 北大核心 2013年第3期331-335,共5页 Chinese Journal of New Drugs
关键词 甲硝唑 缓释片 药代动力学 血药浓度 HPLC metronidazole sustained release tablets pharmacokinetic plasma concentration HPLC
  • 相关文献

参考文献7

二级参考文献17

共引文献9

同被引文献41

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部